SCHEMBL4666121

SCHEMBL4666121

Cc1ccc(S(=O)(=O)Nc2ccc(Nc3cc(-c4cccc5c4oc4ccccc45)ncn3)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
GAA P10253 2/20 0.45
TNNI3K Q59H18 1/20 0.45
CCNT1 O60563 3/20 0.44
CDK9 P50750 3/20 0.44
ALDH1A1 P00352 6/20 0.44
HPGD P15428 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
RAB9A P51151 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
PTPN2 P17706 3/20 0.43
PTPN1 P18031 3/20 0.43
PTPN5 P54829 3/20 0.43
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4666163 0.87 ALDH1A1 (0.42) TNNI3KCCNT1CDK9ALDH1A1HPGD
SCHEMBL4667473 0.86 MEN1 (0.51) MEN1KMT2AGAATNNI3KCCNT1
SCHEMBL1244720 0.80 ALDH1A1 (0.48) MEN1KMT2AGAACCNT1CDK9
SCHEMBL4663808 0.79 ALDH1A1 (0.54) MEN1KMT2AGAATNNI3KCCNT1
SCHEMBL4663914 0.79 PTPN1 (0.48) MEN1KMT2AGAATNNI3KALDH1A1
SCHEMBL4375503 0.79 ALDH1A1 (0.46) MEN1KMT2AGAACCNT1CDK9
SCHEMBL4098710 0.79 CDK9 (0.64) CCNT1CDK9ALDH1A1LMNAALOX15
SCHEMBL4665854 0.78 BACE1 (0.60) MEN1KMT2AGAATNNI3KALDH1A1
SCHEMBL4666195 0.77 TNNI3K (0.50) MEN1KMT2ATNNI3KCCNT1CDK9
SCHEMBL4375500 0.77 ABL1 (0.47) MEN1KMT2AGAACCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US claimed
EP-1709007-A1 N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS Altana Pharma AG (DE) 2006-10-11 EP claimed
WO-2005070900-A1 N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS ALTANA PHARMA AG (DE) 2005-08-04 WO claimed
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed
EP-1709007-A1 N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS Altana Pharma AG (DE) 2006-10-11 EP disclosed
WO-2005070900-A1 N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS ALTANA PHARMA AG (DE) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 MEN1 3892/4885KMT2A 997/4885GAA 3665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.